Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine
- PMID: 3609114
- DOI: 10.1007/BF00543971
Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine
Abstract
A sensitive HPLC assay has been used to determine the effect of food on plasma endralazine levels in 8 patients with essential hypertension. Subjects were investigated whilst on maintenance therapy with endralazine combined with a fixed antihypertensive baseline treatment for at least 4 weeks, samples being collected after the usual oral morning dose of endralazine (5 mg and 10 mg), on two occasions at least 7 days apart. Endralazine was administered with the concomitant therapy in randomised order once 90 min before and once immediately after a standard breakfast. Acetylator status did not affect its pharmacokinetics in the postprandial study after a 5 mg dose, the peak endralazine concentration averaged 57.5% lower and the AUC had fallen significantly by 49.9%, whereas after 10 mg the postprandial peak level and the AUC were 82.9% and 64.7%, lower. In the 5 mg study the mean arterial blood pressure was decreased by 30 mm Hg in the fasting subjects and by 21 mm Hg in the postprandial group. For the 10 mg dose the corresponding values were 35 and 24 mm Hg. The blood pressure lowering effect was only weakly correlated with the food--related reduction in the plasma endralazine levels. The results suggest that endralazine has a similar kinetic interaction with food as that found for hydralazine.
Similar articles
-
Pharmacodynamic and pharmacokinetic studies with the vasodilator endralazine.J Hypertens Suppl. 1984 Dec;2(3):S551-4. J Hypertens Suppl. 1984. PMID: 6599716
-
Clinical pharmacological studies with the vasodilator endralazine in normotensive subjects and essential hypertensives.Int J Clin Pharmacol Res. 1984;4(1):61-9. Int J Clin Pharmacol Res. 1984. PMID: 6469433
-
Endralazine, a new peripheral vasodilator: absence of effect of acetylator status on antihypertensive effect.Lancet. 1983 Mar 26;1(8326 Pt 1):670-1. doi: 10.1016/s0140-6736(83)91967-0. Lancet. 1983. PMID: 6132036 Clinical Trial.
-
Clinical evaluation of endralazine (BO22708), a new vasodilator, in essential hypertension.Clin Exp Hypertens A. 1982;4(8):1409-18. doi: 10.3109/10641968209060798. Clin Exp Hypertens A. 1982. PMID: 6749347
-
Studies in the rat on endralazine, a new antihypertensive drug structurally related to hydralazine.Clin Exp Pharmacol Physiol. 1981 Mar-Apr;8(2):133-9. doi: 10.1111/j.1440-1681.1981.tb00144.x. Clin Exp Pharmacol Physiol. 1981. PMID: 7018762
Cited by
-
Effects of food on clinical pharmacokinetics.Clin Pharmacokinet. 1999 Sep;37(3):213-55. doi: 10.2165/00003088-199937030-00003. Clin Pharmacokinet. 1999. PMID: 10511919 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical